Clusterin Expression in Colorectal Carcinomas

Colorectal cancer is the third most diagnosed cancer, behind only breast and lung cancer. In terms of overall mortality, it ranks second due to, among other factors, problems with screening programs, which means that one of the factors that directly impacts survival and treatment success is early detection of the disease. Clusterin (CLU) is a molecular chaperone that has been linked to tumorigenesis, cancer progression and resistance to anticancer treatments, which has made it a promising drug target. However, it is still necessary to continue this line of research and to adjust the situations in which its use is more favorable. The aim of this paper is to review the current genetic knowledge on the role of CLU in tumorigenesis and cancer progression in general, and discuss its possible use as a therapeutic target in colorectal cancer.

• Publication year

  2023

• Venue

  International Journal of Molecular Sciences

• Publication date

  2023-09-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/ijms241914641PMID 37834086PMCID 10572822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer

  2023cited by this paper
• Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

  2023cited by this paper
• Colorectal cancer statistics, 2023

  2023cited by this paper
• Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer.

  2022influential reference
• Risk Factors for Colorectal Polyps and Cancer.

  2022cited by this paper
• Construction of a Colorectal Cancer Prognostic Risk Model and Screening of Prognostic Risk Genes Using Machine-Learning Algorithms

  2022cited by this paper
• Cancer treatment and survivorship statistics, 2022

  2022cited by this paper
• BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.

  2022cited by this paper
• Clinical management of metastatic colorectal cancer in the era of precision medicine

  2022cited by this paper
• Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer

  2022cited by this paper
• Cancer statistics, 2022

  2022cited by this paper
• Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series

  2021cited by this paper
• A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification.

  2021cited by this paper
• Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type.

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.

  2021cited by this paper
• BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database.

  2021cited by this paper
• Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway

  2021cited by this paper
• The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma

  2021cited by this paper
• Genetic and biological hallmarks of colorectal cancer

  2021cited by this paper
• Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.

  2021cited by this paper
• Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

  2021cited by this paper
• Patient-Derived Colorectal Cancer Organoids Upregulate Revival Stem Cell Marker Genes Following Chemotherapeutic Treatment

  2020cited by this paper
• Colorectal Cancer Immunotherapy: Options and Strategies

  2020influential reference
• Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development

  2020cited by this paper
• Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy.

  2020cited by this paper
• Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies

  2019cited by this paper
• Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer.

  2019cited by this paper
• Brain clusterin protein isoforms and mitochondrial localization

  2019cited by this paper
• High Clusterin (CLU) mRNA expression levels in tumors of colorectal cancer patients predict a poor prognostic outcome.

  2019cited by this paper
• Colorectal cancer

  2019cited by this paper
• Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer

  2019cited by this paper
• Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

  2019cited by this paper
• Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches.

  2019cited by this paper
• sCLU as prognostic biomarker and therapeutic target in osteosarcoma

  2019cited by this paper
• Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2

  2018cited by this paper
• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

  2018cited by this paper
• Phase II Clinical Trial to Evaluate the Efficacy of Transanal Endoscopic Total Mesorectal Excision for Rectal Cancer

  2018cited by this paper
• KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment.

  2018cited by this paper
• A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer

  2018cited by this paper
• New insights into colorectal cancer screening and early detection tests

  2017cited by this paper
• Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

  2017cited by this paper
• Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.

  2017cited by this paper
• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

  2017cited by this paper
• Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study

  2017cited by this paper
• Ku70, Ku80, and sClusterin: A Cluster of Predicting Factors for Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer.

  2017cited by this paper
• Factors that influence treatment delay in patients with colorectal cancer

  2016cited by this paper
• Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015

  2016cited by this paper
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

  2016cited by this paper
• Precision medicine and the FDA's draft guidance on laboratory-developed tests

  2015cited by this paper
• Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Clusterin gene is predominantly regulated by histone modifications in human colon cancer and ectopic expression of the nuclear isoform induces cell death.

  2015cited by this paper
• Colorectal cancer

  2015cited by this paper
• Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study

  2015cited by this paper
• Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

  2015cited by this paper
• Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer

  2015cited by this paper
• Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

  2014cited by this paper
• Colorectal cancer

  2014cited by this paper
• A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer

  2014cited by this paper
• Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists

  2014cited by this paper
• The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases

  2014cited by this paper
• The serrated pathway to colorectal carcinoma: current concepts and challenges

  2013cited by this paper
• Correction: Non-Secreted Clusterin Isoforms Are Translated in Rare Amounts from Distinct Human mRNA Variants and Do Not Affect Bax-Mediated Apoptosis or the NF-κB Signaling Pathway

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer

  2013cited by this paper
• Non-Secreted Clusterin Isoforms Are Translated in Rare Amounts from Distinct Human mRNA Variants and Do Not Affect Bax-Mediated Apoptosis or the NF-κB Signaling Pathway

  2013cited by this paper
• The Molecular Chaperone Apolipoprotein J/Clusterin as a Sensor of Oxidative Stress: Implications in Therapeutic Approaches - A Mini-Review

  2013cited by this paper
• Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

  2012cited by this paper
• Small heat shock proteins in cancer therapy and prognosis.

  2012cited by this paper
• Clusterin and Chemotherapy Sensitivity Under Normoxic and Graded Hypoxic Conditions in Colorectal Cancer

  2012influential reference
• The Role of Clusterin in Alzheimer’s Disease: Pathways, Pathogenesis, and Therapy

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.

  2011cited by this paper
• XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

  2011cited by this paper
• ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability

  2011cited by this paper
• Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

  2011cited by this paper
• Clusterin expression is associated with decreased disease‐free survival of patients with colorectal carcinomas

  2010cited by this paper
• Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer

  2010cited by this paper
• Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays.

  2010cited by this paper
• Chapter 3: The shifting balance between CLU forms during tumor progression.

  2009cited by this paper
• The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas.

  2009cited by this paper
• Regulation of Clusterin Expression in Human Cancer via DNA Methylation

  2009cited by this paper
• Clusterin (CLU) and prostate cancer.

  2009cited by this paper
• CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.

  2009cited by this paper
• Chapter 2: Clusterin (CLU): From one gene and two transcripts to many proteins.

  2009cited by this paper
• Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma

  2009cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Stress‐Induced Retrotranslocation of Clusterin/ApoJ into the Cytosol

  2007cited by this paper
• Classification of colorectal cancer based on correlation of clinical, morphological and molecular features

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases

  2006cited by this paper
• PD‐L2:PD‐1 involvement in T cell proliferation, cytokine production, and integrin‐mediated adhesion

  2005cited by this paper
• Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells

  2005cited by this paper
• Clusterin regulates drug-resistance in melanoma cells.

  2005cited by this paper
• DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor.

  2005cited by this paper
• Up‐regulated expression of cytoplasmic clusterin in human ovarian carcinoma

  2005cited by this paper
• Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

  2004cited by this paper
• Modulation of different clusterin isoforms in human colon tumorigenesis

  2004cited by this paper
• Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis

  2004cited by this paper

• CRISPR integrated biosensors: A new paradigm for cancer detection.

  2025cites this paper
• Clinical implications of serum adropin and clusterin in chronic renal failure patients who received hemodialysis.

  2025cites this paper
• Construction and validation of predictive model based on endoplasmic reticulum stress-related genes for triple-negative breast cancer

  2025cites this paper
• Targeting CAD with a tumor microenvironment-responsive nano-heterojunction for synergistic induction of cuproptosis and inhibition of colorectal cancer progression

  2025cites this paper
• Therapeutic Potential of Clusterin Inhibition in Human Cancer

  2024cites this paper
• Clusterin protects mature dendritic cells from reactive oxygen species mediated cell death

  2023cites this paper